Solid Tumor Program News Today

Established clinician researcher will focus on novel treatments and clinical trials for difficult-to-treat childhood cancers.

Established clinician researcher will focus on novel treatments and clinical trials for difficult-to-treat childhood cancers.

Provides fiscal year 2025 revenue guidance of $12 - $16 millionUS pilot trial of LungFit® PRO to treat viral community acquired pneumonia (VCAP) u...

22.06.2023 - Successfully completed phase 1 of U.S. commercial launch, with multiple hospitals contracted, and have initiated phase 2 of launch for LungFit PH for the treatment of term and near-term neonates with hypoxic respiratory failure Presented positive ...

Rhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.

BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein,

The Rush brothers, Tristen, Caison and Carter, share a lot in common, including the same cancer.

WCCB Charlottes CW February 10, 2021 CHARLOTTE, N.C. (News Release) — Isabella Santos Foundation (ISF) a Charlotte childhood cancer charity was created in honor of Isabella Santos who lost her fight to neuroblastoma, a rare pediatric cancer, at just seven years old. On March 9th, Isabella would have turned 16-years-old. While she only lived seven years, Charlotte, the nation, and the world feel her astounding impact through the creation of the ISF Rare & Solid Tumor Program at Atrium Health L...